Observing the effects of proton therapy in lymphoma patients
Multicenter Registry Study on Proton Radiotherapy for Mediastinal Lymphomas
This study tests if proton therapy can effectively treat young patients with mediastinal lymphoma while causing fewer side effects compared to traditional radiation methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Heidelberg) |
| Trial ID | NCT04613388 on ClinicalTrials.gov |
What this trial studies
This study aims to document the effectiveness and side effects of proton radiotherapy in patients with mediastinal lymphoma. It focuses on reducing therapy-associated toxicity, particularly in young patients who are at risk for long-term complications from conventional radiation methods. By utilizing modern radiation techniques like proton therapy, the study seeks to minimize radiation exposure to critical organs such as the heart and lungs. Data collected will help inform future treatment planning and feasibility for this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed lymphoma requiring mediastinal radiotherapy.
Not a fit: Patients under 18 years old or those who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer treatment options for lymphoma patients, reducing long-term side effects associated with radiation therapy.
How similar studies have performed: Other studies have shown promising results with proton therapy in reducing side effects, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Histologically confirmed lymphoma according to WHO * Patient consent * Patient age ≥18 years. * Presence of the need for mediastinal radiotherapy and the presumed benefit of mediastinal radiotherapy using protons in comparison to photon radiation (e.g. improved heart, lungs, and breast protection compared to photon radiation). * Ability of the patient to give consent Exclusion Criteria: Age \<18 years * Non-consent of the patient to the disclosure of his data * Cancellation of the patient's participation in the study
Where this trial is running
Heidelberg
- University Hospital Heidelberg — Heidelberg, Germany (Recruiting)
Study contacts
- Principal investigator: Laila König, MD — University Hospital Heidelberg
- Study coordinator: Laila König, MD
- Email: laila.könig@med.uni-heidelberg.de
- Phone: +49 6221
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.